Scripps researchers discovered a new set of antibodies (blue and gray) that can neutralize influenza by binding to the anchor region of influenza HA (pink and purple).
Credit: Julianna Han, Ward Lab
A new antibody discovered in the blood of some people vaccinated against or infected with influenza can recognize a broad variety of flu viruses.
Scientists at Scripps Research, University of Chicago and Icahn School of Medicine at Mount Sinai have identified a new Achilles’ heel of influenza virus, making progress in the quest for a universal flu vaccine. Antibodies against a long-ignored section of the virus, which the team dubbed the anchor, have the potential to recognize a broad variety of flu strains, even as the virus mutates from year to year, they reported Dec. 23, 2021 in the journal Nature.
“It’s always very exciting to discover a new site of vulnerability on a virus because it paves the way for rational vaccine design,” says co-senior author Andrew Ward, PhD, professor of Integrative Structural and Computational Biology at Scripps Research. “It also demonstrates that despite all the years and effort of influenza vaccine research there are still new things to discover.”
“By identifying sites of vulnerability to antibodies that are shared by large numbers of variant influenza strains we can design vaccines that are less affected by viral mutations,” says study co-senior author Patrick Wilson, MD, who was previously at the University of Chicago and recently recruited to Weill Cornell Medicine as a professor of pediatrics and a scientist in the institution’s Gale and Ira Drukier Institute for Children’s Health. “The anchor antibodies we describe bind to such a site. The antibodies themselves can also be developed as drugs with broad therapeutic applications.”
In a typical year, influenza affects more than 20 million people in the United States and leads to more than 20,000 deaths. Vaccines against influenza typically coax the immune system to generate antibodies that recognize the head of hemagglutinin (HA), a protein that extends outward from the surface of the flu virus. The head is the most accessible regions of HA, making it a good target for the immune system; unfortunately, it is also one of the most variable. From year to year, the head of HA often mutates, necessitating new vaccines.
Researchers have designed experimental influenza vaccines to be more universal, spurring the body to create antibodies against the less-variable stalk region of HA, which extends like a stem between the influenza virion and the HA head. Some of these universal flu vaccines are currently in early clinical trials.
In the new study, a collaborative team of scientists characterized 358 different antibodies present in the blood of people who had either been given a seasonal influenza vaccine, were in a phase I trial for an experimental, universal influenza vaccine, or had been naturally infected with influenza.
Many of the antibodies present in the blood of participants were antibodies already known to recognize either the HA head or stalk. But a collection of new antibodies stood out; the antibodies bound to the very bottom of the stalk, near where each HA molecule is attached to the membrane of the flu virion.
The co-first authors of the manuscript—Julianna Han, a staff scientist in the Ward lab, and Jenna Guthmiller, a postdoctoral fellow at the University of Chicago—named this section of HA the anchor, and began studying it further. In all, the scientists identified 50 different antibodies to the HA anchor, from a total of 21 individuals. The antibodies, they discovered, recognized a variety of H1 influenza viruses, which account for many seasonal flu strains. Some of the antibodies were also able to recognize pandemic H2 and H5 strains of influenza in lab tests. And in mice, the antibodies successfully protected against infection by three different H1 influenza viruses.
“In order to increase our protection to these highly mutating viruses, we need to have as many tools as we can,” says Han. “This discovery adds one more highly potent target to our repertoire.” Importantly, these antibodies appear to be fairly common in people, and belong to a class of antibodies that any person’s body can produce—an important consideration in designing a vaccine to spur their development.
“The human immune system already has the ability to make antibodies to this epitope, so it’s just a matter of applying modern protein engineering methods to make a vaccine that can induce those antibodies in sufficient numbers,” adds Guthmiller.
The researchers say that future, improved iterations of a universal vaccine could more purposefully aim to generate anchor antibodies. Until now, scientists designing universal vaccines hadn’t paid attention to whether the anchor region of the stem was included as a target. Ideally, a universal influenza vaccine will lead to antibodies against multiple sections of the virus—such as both the HA anchor and the stalk—to increase protection to evolving viruses.
The researchers are planning future studies on how to design a vaccine that most directly targets the HA anchor of different influenza strains.
More from: The Scripps Research Institute | University of Chicago | Icahn School of Medicine at Mount Sinai | University of Innsbruck | Fred Hutchinson Cancer Research Center | University of Maryland School of Medicine
The Latest on: Universal influenza vaccine
- Is a universal flu vaccine within reach?on July 5, 2022 at 8:15 am
The National Institutes of Health (NIH) have started human trials for an experimental universal flu vaccine that has shown promise in animal studies.
- Universal Flu Vaccine Gets Closer to Reality As Phase 1 Testing Startson July 5, 2022 at 6:45 am
A new form of the flu vaccine is currently under trial to help protect against all forms of influenza. The National Institutes of Health recently announced it is beginning its phase one trial for a ...
- New Universal Flu Vaccine Protects Against Influenza A Viruseson July 5, 2022 at 6:28 am
New innovative universal flu vaccine can fight against different strains and subtypes of influenza A viruses in young and aged populations.
- A New Type of Universal Flu Vaccineon July 5, 2022 at 6:02 am
Researchers have created a new 'universal' flu vaccine, which is directed against type A influenza viruses. It was created using portions of two im | Immunology ...
- New universal flu vax offers broad protection against influenza A viruseson July 4, 2022 at 10:00 am
A new universal flu vaccine, constructed with key parts of the influenza virus, offers broad cross protection against different strains and subtypes of influenza A viruses in young and aged population ...
- New universal flu vaccine offers broad protection against influenza A virus infections, researchers findon July 1, 2022 at 11:40 am
A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses in young and aged populations, ...
- Universal Flu Vaccine Enters Clinical Trials in Humanson July 1, 2022 at 10:51 am
The test will inoculate 100 volunteers with a vaccine that protected mice from lethal doses of six different flu strains ...
- Novel universal flu vaccine confers protection against different strains and subtypes of influenza A viruseson June 30, 2022 at 4:19 pm
The findings, published in the journal npj Vaccines, show that M2e-stalk protein vaccination induced broad protection against different influenza virus strains and subtypes by universal vaccine ...
- US begins testing a universal flu vaccineon June 30, 2022 at 8:24 am
Story at a glance Flu vaccine efficacy varies from year to year due to a host of factors. In an effort to better protect against influenza, researchers developed a whole-virus vaccine. Previous trials ...
- Universal flu vaccine developed by US government begins human trialson June 29, 2022 at 9:53 pm
Researchers at the National Institutes of Health (NIH) are beginning a Phase 1 human trial to test a new universal flu vaccine. The trial will test the novel vaccine being delivered either as a nasal ...
via Bing News
The Latest on: Universal influenza vaccine
via Google News